Optical Biopsy to Improve the Diagnosis of Kidney Cancer
|ClinicalTrials.gov Identifier: NCT02073110|
Recruitment Status : Unknown
Verified February 2014 by P.G.K. Wagstaff, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).
Recruitment status was: Recruiting
First Posted : February 27, 2014
Last Update Posted : February 27, 2014
Data from the American Cancer Society shows a 70% increase in incidence of kidney and renal pelvis cancer between 2000 and 2010. This increase is attributed to small renal masses (SRM) that are incidentally discovered by abdominal radiological imaging. However, 30% of resected SRMs appear benign on histological examination. Conventional biopsy is currently used to provide pathological information prior to resection. However, its non-diagnostic value is high, up to 33% in SRMs, showing the need for diagnostic improvement.
The investigators have shown that optical biopsy (OB) can differentiate malignant from benign tissue and tumor subtypes. However, translation to the clinic requires a phase 2 clinical study. The investigators will use an OB probe that can be combined with a needle puncture during classical biopsy procedures, additionally providing real time micro-scale images containing quantitative information about tissue properties. The investigators are convinced that OB will greatly improve the diagnosis of renal tumor pathology.
|Condition or disease||Intervention/treatment|
|Kidney Cancer||Device: Percutaneous Optical Biopsy (OCT and DRS)|
Renal biopsies can be used in patients with renal mass lesions to diagnose whether it concerns a malignant or benign mass. In case of malignancy, surgery will be the following step. However, 7 to 33% of biopsies are non-diagnostic, what can result in unnecessary surgery (even up to 30% in small renal masses). The investigators think that optical biopsy (OB), a new diagnostic tool based on the absorption en reflection of light in tissues, reduces the non-diagnostic biopsy rate. This could have a direct impact on the quality of life of the patients that are therefore scheduled for an unnecessary surgical procedure. Also, concerns about overtreatment have led to the concept of focal therapy, a selective patient tailored nephron sparing surgical or ablation technique of a lesion, reducing lifetime morbidity and side effects without compromising life expectancy. For this novel form of treatment, accurate identification, grading and demarcation of a lesion is crucial and OB is the ideal platform to provide this approach to an improved cure.
- The accuracy of DRS and OCT in the diagnostic of renal malignancy
- The accuracy of DRS and OCT in the diagnostic of renal malignancy and in distinguishing among the 3 main RCC subtypes
- The accuracy of the combination of the DRS and OCT
This is a prospective, observational, multi-centre in-vivo study.
Patients ≥ 18 years of age, with a solid enhancing renal mass suspected for renal cell carcinoma (RCC) and candidates for active (surgical) treatment of the renal mass.
Patients will receive an ultrasound guided percutaneous OB followed by a Core biopsy (CB) during the same procedure. The planned institutional surgical protocol will be followed irrespective of the results of OB and CB. During surgery (radical/partial, open/laparoscopic, percutaneous ablation) a new set of DRS and OCT measurements of the tumor and normal tissue will be performed.
Main study parameters/endpoints:
- To determine the accuracy of OB to differentiate renal tumor pathology from benign tissue by means of minimal invasive quantitative DRS and OCT.
- To determine the differentiation capability of OCT this combined technique to distinguish between the three most common RCC sub-types.
- To determine whether OB is a good alternative to the percutaneous biopsy for diagnosing renal cancer.
|Study Type :||Observational|
|Estimated Enrollment :||194 participants|
|Official Title:||Optical Biopsy to Improve the Diagnosis of Kidney Cancer: a Prospective, Observational, Multicentre, In-vivo Study|
|Study Start Date :||August 2013|
|Estimated Primary Completion Date :||December 2016|
|≥ 18 years, solid enhancing renal mass suspected for RCC||Device: Percutaneous Optical Biopsy (OCT and DRS)|
- The sensitivity and specificity of DRS and OCT in the detection of renal malignancy [ Time Frame: Participants will undergo OCT/DRS measurements within 2 weeks after inclusion ]By measuring the OCT attenuation coefficient (µOCT) and the DRS optical blood absorption (µaHb), and correlating these values to the histopathology results.
- The sensitivity and specificity of DRS and OCT in differentiating between the three main RCC subtypes [ Time Frame: Participants will undergo OCT/DRS measurements within 2 weeks after inclusion ]By measuring the OCT attenuation coefficient (µOCT) and the DRS optical blood absorption (µaHb), and correlating these values to the histopathology results.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02073110
|Contact: MP Laguna Pes, MD. PhD.||+firstname.lastname@example.org|
|Free University Medical Center||Not yet recruiting|
|Amsterdam, Netherlands, 1081 HV|
|Contact: RJA van Moorselaar, MD. PhD. +31204440272 Rja.email@example.com|
|Academic Medical Center||Recruiting|
|Amsterdam, Netherlands, 1105 AZ|
|Contact: MP Laguna Pes, MD. PhD. +31205666928 firstname.lastname@example.org|
|Contact: Peter Wagstaff, MD. +31205666493 email@example.com|
|Sub-Investigator: Peter Wagstaff, MD|
|Principal Investigator:||MP Laguna Pes, MD. PhD.||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|
|Study Chair:||JJMCH de la Rosette, MD. PhD.||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|